Non-small cell lung cancer (NSCLC)
REZILIENT 4
Phase 3 Study of Zipalertinib plus adjuvant chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)..
Trial overview
Clinical Area
Medical Oncology
Disease
Non-small cell lung cancer (NSCLC)
Disease site
Lung & bronchus
Study Phase
III
Trial Identifiers
Registration number: NCT07128199
GenesisCare Location(s)
Principal Investigator(s)